Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma
Novo Nordisk receives Health Canada approval for Saxenda (liraglutide) for the treatment of chronic weight management
Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed
LONDON, February 26, 2015 /PRNewswire/ --
Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Feb.
Universal Health Services, Inc. Reports 2014 Fourth Quarter And Full Year Earnings And 2015 Earnings Guidance
Consolidated Results of Operations, As Reported - Three and twelve-month periods ended December 31, 2014 and 2013:
KING OF PRUSSIA, Pa.
Johnson & Johnson Announces Formation of New Health and Wellness Platform Designed to Transform Health Care Delivery and Improve the Patient Experience
New Patient Athlete™ Program Demonstrates Comprehensive Approach to Driving Sustained Behavior Change and Improved Outcomes
Launch of the Anti-Cancer Agent / BRAF Inhibitor "Zelboraf®" - Contribution to the Treatment of Melanoma by Personalized Healthcare -
NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C
THOUSAND OAKS, Calif., Feb.